NA-Semax

An acetylated analog of Semax with enhanced metabolic stability and reportedly greater potency in promoting BDNF expression. The N-acetyl modification reduces susceptibility to aminopeptidase cleavage, extending the peptide's active duration and potentially amplifying its neurotrophic effects.

• Same melanocortin receptor (MC3/MC4) and BDNF-promoting mechanisms as Semax
• N-acetyl group provides resistance to aminopeptidase degradation at the N-terminus
• Enhanced blood-brain barrier penetration increases central neurotrophic effects
• Modulates dopaminergic and serotonergic neurotransmission with improved pharmacokinetic profile

• Active seizure disorders
• Pregnancy or breastfeeding
• Known hypersensitivity to ACTH-derived peptides

Store at 2–8°C (36–46°F) for up to 3 months. For long-term storage, keep at -20°C (-4°F). Once reconstituted, refrigerate and use within 21 days. Protect from light.

NA-Semax builds on the extensive Russian clinical research behind standard Semax by incorporating an N-acetyl modification for improved pharmacokinetics. Preclinical studies suggest that the acetylated form may produce greater BDNF elevation per dose compared to unmodified Semax. While it lacks the independent clinical trial data of its parent compound, the pharmacological rationale for the modification is well-established, and it has become one of the most popular nootropic peptides in research communities seeking enhanced potency over standard Semax.